Eli Lilly (LLY) entered a merger agreement on January 7, 2026, to acquire Ventyx Biosciences, Inc. (VTYX) in an all-cash deal valued at $1.2 billion.
Lilly will acquire all of the outstanding shares of Ventyx for $14 per share of common stock in an all-cash transaction, representing a 1.97% premium from the stock’s last close.
Ventyx is a clinical-stage biopharmaceutical company focused on creating oral treatments for inflammatory and autoimmune diseases, including conditions affecting the heart, brain, and immune system.
Eli Lilly is a pharmaceutical company developing innovative medicines to address some of the world’s most serious health challenges, including diabetes, cancer, and neurodegenerative diseases.
A day ago, WSJ reported that Eli Lilly was in advanced talks to acquire Ventyx for more than $1 billion. The stock was trading at $7.82, which then shot up as it was revealed that Lilly could pay $14 for Ventyx.
The deal is expected to close in the first half of 2026.
Ventyx was advised by Jefferies and Moelis & Co. as financial advisors and by Wilson Sonsini Goodrich & Rosati as legal counsel. Eli Lilly was advised by BofA Securities as financial advisor and by Ropes & Gray as legal counsel.
For further information on this M&A transaction, please visit the Deal Metrics page here:
Deal Metrics for the acquisition of Ventyx Biosciences, Inc. (VTYX) by Eli Lilly and Company (LLY)
The Deal Metrics page for each merger or acquisition includes:
– A spread history chart of the merger from announcement through eventual completion or failure.
– Every event as the merger progresses through the expiration of the HSR period, various regulatory approvals, shareholder votes, etc.
– News and SEC filings.
– A history of deal updates.
– And much more.
Disclaimer: Please conduct your own due diligence before buying or selling any securities mentioned in this article. We do not warrant the completeness or accuracy of the content or data provided in this article.
Editor’s Note: Baranjot Kaur contributed to this article